UA102849C2 - Способ продолжительного лечения эндометриоза и фибромы матки - Google Patents

Способ продолжительного лечения эндометриоза и фибромы матки

Info

Publication number
UA102849C2
UA102849C2 UAA201014039A UAA201014039A UA102849C2 UA 102849 C2 UA102849 C2 UA 102849C2 UA A201014039 A UAA201014039 A UA A201014039A UA A201014039 A UAA201014039 A UA A201014039A UA 102849 C2 UA102849 C2 UA 102849C2
Authority
UA
Ukraine
Prior art keywords
endometriosis
treatment
estrogen
uterine fibroids
methods
Prior art date
Application number
UAA201014039A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джозеф С. Подольски
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of UA102849C2 publication Critical patent/UA102849C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение касается способа продолжительного лечения эстрогензависимого состояния, выбранного из группы, которая состоит из эндометриоза и фибромы матки, который включает введение композиции, которая содержит эффективное количество селективного модулятора рецепторов прогестерона, выбранного из CDB-4124 (21-метокси-17α-ацетокси-11β-(4-N,N-диметиламинофенил)-19-нонпрегна-4,9-диен-3,20-диона) и 17α-ацетокси-1lβ-(4-N,N-диметиламинофенил)-19-норпрегна-4,9-диен-3,20-диона, согласно периодическому режиму введения.
UAA201014039A 2008-04-28 2009-04-27 Способ продолжительного лечения эндометриоза и фибромы матки UA102849C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28
PCT/US2009/041826 WO2009134718A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Publications (1)

Publication Number Publication Date
UA102849C2 true UA102849C2 (ru) 2013-08-27

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014039A UA102849C2 (ru) 2008-04-28 2009-04-27 Способ продолжительного лечения эндометриоза и фибромы матки

Country Status (24)

Country Link
US (2) US8426394B2 (ru)
EP (1) EP2293797B1 (ru)
JP (1) JP5791499B2 (ru)
KR (2) KR20130059442A (ru)
CN (2) CN105616427A (ru)
AR (1) AR071516A1 (ru)
AU (1) AU2009241355B2 (ru)
BR (1) BRPI0911563A2 (ru)
CA (1) CA2722753C (ru)
CL (1) CL2009001010A1 (ru)
DK (1) DK2293797T3 (ru)
EA (3) EA032646B1 (ru)
ES (1) ES2561810T3 (ru)
IL (1) IL208844A0 (ru)
ME (1) ME01123B (ru)
MX (1) MX2010011272A (ru)
MY (1) MY161059A (ru)
NI (1) NI201000183A (ru)
NZ (1) NZ589533A (ru)
SG (1) SG10201408483QA (ru)
TW (1) TWI477276B (ru)
UA (1) UA102849C2 (ru)
WO (1) WO2009134718A1 (ru)
ZA (1) ZA201007529B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
NZ702467A (en) * 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
ES2688821T3 (es) * 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
BR9408067A (pt) * 1993-11-16 1996-12-24 Schering Ag Tratamento de distúrbios de contratilidade uterina com um substrato e/ou um doador de sintase de óxido nitrico ou um inibidor de óxido nitrico
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
KR100370908B1 (ko) * 1995-02-02 2003-04-10 쉐링 악티엔게젤샤프트 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6861415B2 (en) * 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
ES2307604T3 (es) * 2000-03-17 2008-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services 19-norpregnadienodiona 17-a sustituidos, 11-b-sustituido-4-arilo y 21-sustituidos como nuevos agentes antiprogestacionales.
IN191020B (ru) * 2000-03-28 2003-09-13 Dabur Res Foundation
ATE272006T1 (de) 2000-04-03 2004-08-15 Astenjohnson Inc Vorgewellte bandkomponente
CN1512886A (zh) * 2000-10-18 2004-07-14 ���ֹɷݹ�˾ 抗孕激素预防和治疗激素依赖性疾病的用途
MXPA04000097A (es) 2001-07-09 2004-05-21 Zonagen Inc Metodo y materiales para el tratamiento de deficiencias de testosterona en varones.
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
NZ552720A (en) * 2004-07-09 2010-02-26 Population Council Inc Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
HUE051484T2 (hu) * 2006-10-24 2021-03-01 Allergan Pharmaceuticals Int Ltd Készítmények és eljárások az endometriális proliferációk elnyomására
BRPI0806572A2 (pt) * 2007-01-17 2014-05-06 Repros Therapeutics Inc Composição e método de produção de efeito antiprogestacional, de indução menstrual, de tratamento de endometriose, da dismenorreia, de tumores dependentes de hormônio endócrino, de meningiomas, de fibriomas uterinos, de inibição da proliferação endometrial uterina, de indução de trabalho de parto e de contracepção.
AU2008237246B2 (en) 2007-04-05 2014-06-05 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
PL2148681T3 (pl) * 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2482914A1 (en) 2009-09-29 2012-08-08 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
JP2011518845A (ja) 2011-06-30
ZA201007529B (en) 2011-07-27
KR20110014162A (ko) 2011-02-10
WO2009134718A8 (en) 2010-09-23
US20130289008A1 (en) 2013-10-31
EA201401347A1 (ru) 2015-07-30
JP5791499B2 (ja) 2015-10-07
US8426394B2 (en) 2013-04-23
CN105616427A (zh) 2016-06-01
AR071516A1 (es) 2010-06-23
KR20130059442A (ko) 2013-06-05
SG10201408483QA (en) 2015-02-27
IL208844A0 (en) 2011-01-31
MX2010011272A (es) 2010-12-21
DK2293797T3 (en) 2016-01-11
EA032646B1 (ru) 2019-06-28
BRPI0911563A2 (pt) 2016-07-12
CA2722753A1 (en) 2009-11-05
MY161059A (en) 2017-04-14
US8735381B2 (en) 2014-05-27
EA201990835A2 (ru) 2019-08-30
NZ589533A (en) 2012-06-29
TW200950786A (en) 2009-12-16
EA201990835A3 (ru) 2019-12-30
TWI477276B (zh) 2015-03-21
CL2009001010A1 (es) 2009-06-19
CN102014923A (zh) 2011-04-13
US20110046098A1 (en) 2011-02-24
EA201071249A1 (ru) 2011-08-30
EP2293797B1 (en) 2015-11-11
EP2293797A1 (en) 2011-03-16
AU2009241355A1 (en) 2009-11-05
ME01123B (me) 2013-03-20
CA2722753C (en) 2018-07-03
WO2009134718A1 (en) 2009-11-05
ES2561810T3 (es) 2016-03-01
NI201000183A (es) 2012-06-06
AU2009241355B2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
UA102849C2 (ru) Способ продолжительного лечения эндометриоза и фибромы матки
MY150763A (en) Compositions and methods for suppressing endometrial proliferation
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MX2014004202A (es) Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión.
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
MX2020006431A (es) Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
IL193479A0 (en) Modulators of muscarinic receptors
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
AU2019284019A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
TN2017000482A1 (en) Selective progesterone receptor modulator (sprm) regimen.
MX2009009332A (es) Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.
MY172530A (en) Method for treating gynecological diseases
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза
TN2015000454A1 (en) Progesterone receptor antagonist dosage form
UA90568U (ru) Способ комплексной терапии овец и коз с гиполютеолизом
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids
UA104730C2 (en) Isoquinolinone derivatives as nk3 antagonists